{"id":"W4280541127","doi":"10.1136/jitc-2021-004076","title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Cilag; Foundation Medicine; Takeda Oncology; Chugai Pharmaceutical; Novartis Pharma; Genentech; Daiichi Sankyo Europe; National Cancer Institute; Servier; Eisai; Basilea Pharmaceutica; AstraZeneca; Institut National Du Cancer; Seagen; Agios Pharmaceuticals; Eisai Canada; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Boston Pharmaceuticals; Taiho Pharmaceutical; F. Hoffmann-La Roche; Yale University; Bayer HealthCare; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atezolizumab; Blockade; Solid tumor; Medicine; Immune checkpoint; Immune system; Oncology; Cancer research; Internal medicine; Immunology; Immunotherapy; Pembrolizumab; Cancer; Receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001053192,0.0005466001,0.001216006,0.000279093,0.000182351,0.0005151841,0.000388647,0.00041024,0.0009277809],"category_scores_gemma":[0.0006988535,0.0002476549,0.0006913616,0.000264852,0.0003523924,0.0003153386,0.0002092259,0.001314263,0.000274104],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005504628,"about_ca_system_score_gemma":0.0007170311,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004078829,"about_ca_topic_score_gemma":0.001033747,"domain_scores_codex":[0.9997055,0.0001395882,0.00002207625,0.00004830558,0.00003582205,0.00004872592],"domain_scores_gemma":[0.999619,0.00009019605,0.0001023092,0.00002604664,0.00002018484,0.0001422233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4262984,0.04570897,0.06242708,0.001217989,0.001869522,0.0008847377,0.0005779015,0.007895559,0.124288,0.0002828668,0.00357472,0.3249742],"study_design_scores_gemma":[0.1748037,0.7227908,0.07572568,0.00008204082,0.0007144657,0.001415394,0.00006882265,0.005479323,0.01357643,0.0001530694,0.005153318,0.00003689077],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980617,0.001009102,0.0001550761,0.00008280504,0.00002070231,0.0001581171,0.00009553006,0.00001679286,0.000400201],"genre_scores_gemma":[0.9982458,0.000503264,0.0004058419,0.0001146241,0.00003503383,0.0001361,0.0002571836,0.00000517737,0.0002969419],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001216006,"threshold_uncertainty_score":0.005569935,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01447742620359424,"score_gpt":0.325284274372232,"score_spread":0.3108068481686377,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}